Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus KERLONE.
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity or membrane stabilizing activity. Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors predominantly in cardiac tissue.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min IV for 4 minutes. Titrate by 50 mcg/kg/min increments every 4 minutes as needed to maximum of 200 mcg/kg/min. For double-strength (20 mg/mL) formulation, adjust infusion rate accordingly.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes. Clinical context: ultra-short acting beta-blocker, steady state achieved within 30 minutes.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Rapid metabolism by red blood cell esterases; metabolites are inactive. Less than 2% excreted unchanged in urine.
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker